Dr. Bu Hong, Director of Pathology Research Laboratory at West China Hospital, Confirms Participation in the Digital Pathology and Precision Diagnostics Forum at the 2019 Future Healthcare 100 Summit

As Precision Medicine Gains Favor, How Can the Value of Pathological Diagnosis as the Industry’s “Gold Standard” Be Further Highlighted?

As Artificial Intelligence Enters Numerous Medical Subspecialties, What Sparks Will Fly from the Convergence of AI and Pathology?

After two months of repeated communication and discussion,2019 Future Healthcare 100 Conference Sub-forum – Digital Pathology and Precision Diagnostics ForumBe the first to determine, and will be inDecember 21, 2019, 2:00 PM,atBeijing Jiuhua MountainSolemnly held on schedule.Professor Bu Hong, Director of the Department of Pathology, West China Hospital, Sichuan UniversityConfirmed attendance.

The forum aims to focus on the trends of digitalization, intelligence, and precision in pathology, centering on hot topics such as integrated solutions for pathological diagnosis, immunohistochemistry technology, next-generation sequencing, and digital PCR, to explore the future trends and practical advancements of pathological diagnosis in the realms of digitalization, intelligence, and precision.

The specific agenda for the forum is as follows:

Article 1:The History of Development of Pathological Diagnosis in China: From Routine IVD to Precision IVD

Guest:Bu Hong | Chairman of the Chinese Society of Pathology, Chinese Medical Association; Professor, Department of Pathology, West China Hospital, Sichuan University

Proposed Agenda:Future Pathology:Intelligence & Cloudification

From digital pathology teleconsultation networks to regional network-based pathology diagnostic platforms, and further to cloud-based pathology platforms, where is the future of pathology heading? The emergence of cloud pathology has accelerated the development of third-party imaging centers, making remote pathology diagnosis more convenient. As digital pathology transitions from a "conceptual" form of telemedicine to practical application, in what direction will the trends toward intelligence and cloud integration lead the industry?

Guest:Zhou Mi | Managing Partner, Puhua Capital

Proposed Agenda:Report "Insights:From General IVD to Precision IVD》

Precision diagnosis is the prerequisite for precision medicine, and the precision medicine sector is expected to create a blue-ocean diagnostic market worth hundreds of billions of yuan by 2030. Conventional IVD (in vitro diagnostics) is gradually transitioning toward precision IVD, making digital innovation in pathology a strategic high ground for industry competition. Against this backdrop, what digital innovations have pathology companies implemented? Which corporate case studies are worthy of discussion and reference?

Article 2:Precision Medicine Guided by Precision Diagnostics

Guest:Qi Hua | CEO of Senot Bio

Proposed Agenda:Application of Tumor Pathological Diagnosis in Precision Medicine

In China, there are more than 10,000 new cancer cases and 6,000 cancer-related deaths every day on average. Pathological diagnosis has become the cornerstone of cancer prevention and treatment. After two decades of development, what progress has immunohistochemistry, a key diagnostic marker in pathology departments, made in clinical practice? What possibilities has liquid biopsy technology brought?

Guest:Gao Zhibo | CEO of Yuce Biotech

Proposed Agenda:Current Status and Trends in Precision Immuno-Oncology Diagnosis and Treatment

As the clinical application of immunotherapies becomes increasingly widespread, identifying biomarkers that predict efficacy, resistance, and toxicity, and even guide the selection of combination regimens, has become a critical endeavor. What is the essence of tumor immune diagnostics? What are the current status and future trends in precision immuno-oncology diagnosis and treatment? With the growing number of approved tumor immunotherapies, how will traditional radiotherapy and chemotherapy evolve in the future?

Part III:Digitalization and AI-Powered Diagnostics: The Wings Propelling the Pathology Industry’s Ascent

Guest:Zhang Yang | Co-founder, Executive Director, and President of Hengdao Pathology

Proposed Agenda:Practice and Reflections on Digital and Intelligent Third-Party Pathology Services

The integration of precision medicine and AI in pathology has become an established trend. AI technology has been proven to significantly enhance the efficiency of pathological testing, alleviate the shortage of pathologists, and reduce turnaround time. How can scenarios, data, and algorithms be organically integrated to create a closed-loop AI application? Furthermore, how can the expertise of pathology specialists be disseminated to grassroots pathology departments and medical institutions through digital means?

Guest:Huang Chunbo | General Manager of Huayin Health

Proposed Agenda:Case Studies in Pathology Business Marketing Practices

How can remote pathology services, which can be conducted anytime and anywhere without geographical or temporal constraints and support multi-site collaborative consultations, further improve their service systems to enhance coverage and service efficiency in promoting the equalization of healthcare services? How should molecular pathology product solutions be developed? How should pathological subspecialties be established?

Final Chapter:Reflections on the Construction of Digital Pathology Departments

Guest:Zhou Mi | Managing Partner, Puhua Capital

Qi Hua | CEO of Senot Bio

Gao Zhibo | CEO of Yuce Bio

Song Zhigang | Deputy Director, Department of Pathology, Chinese PLA General Hospital (Tentative)

Discussion:Reflections on the Construction of Digital Pathology Departments

The primary mission of the pathology department is to provide clear disease diagnoses and precise disease classifications to guide clinical treatment. While pathology departments in China have entered a period of rapid development, they still face significant challenges in management and digitalization. How should pathology departments leverage digital tools to enhance the quality and efficiency of pathological examinations?

With more than half of 2019 behind us, we have witnessed profound changes in the environment of China’s big health industry: the full implementation of the “4+7” volume-based procurement program, the release of the new National Essential Medicines List, the publication of the first batch of the National Key Monitoring List for Rational Drug Use, and comprehensive adjustments to the National Reimbursement Drug List. The introduction of these numerous policies has left the industry overwhelmed.

Meanwhile, the broader health industry has also seen remarkable activity. The internet is increasingly penetrating the healthcare sector, enhancing service efficiency and extending service reach in the commercial realm, while fostering new business models. Artificial intelligence (AI) has begun to be applied in clinical diagnosis and treatment, drug development, and improvements in business efficiency, yielding positive results. Furthermore, advancements in 5G and quantum computing will further expand the scope for AI research, development, and application.

Of greater concern is that the global economy is undergoing profound structural changes, and population aging is profoundly impacting and reshaping the world.

This represents a reform within the ecosystem of the broader health and wellness industry. The breakthrough expansion of China’s health and wellness sector has opened up broader prospects for the global industry as a whole. Today, the convergence of three key factors—policy environment, technological landscape, and demand potential—is poised to drive new growth in the development and expansion of China’s health and wellness industry. This incremental growth often signals that the sector is entering an entirely new phase.

VCBeat’s 2019 Top 100 Future Healthcare Conference, themed “Incremental Value of Life,” will center on the triple factors of policy environment, technological landscape, and demand space. It aims to comprehensively showcase the innovation ecosystem in China’s healthcare sector, foster robust industry exchange and interaction, and create a premier event for the integration of industry and capital.

Five Major Product Pillars: Five Themed Summits and Over 10 Sub-sector Forums, the Future Healthcare Top 100 Rankings and Awards, the Future Healthcare Top 100 Series Reports, the Future Healthcare Top 100 Exhibition, and a Series of Networking Events.

Among them, the forums include:Future Healthcare Main Forum, Top 100 Summit, Future Healthcare Leaders Summit, Future Healthcare Cross-Industry Summit, Health & Medical Fund Partners Summit, China-Japan Health Industry Development Forum, Healthy City Development Forum, Innovative Drugs Forum, Innovative Health Insurance Forum, Digital Pathology and Precision Diagnostics Forum, Health Management Forum, Consumer Healthcare Forum, Internet Hospital Forum, Smart Hospital Construction Forum, Pharmaceutical Digital Marketing Forum, Biotechnology Forum, Medical AI Forum

Also"Future Industry Tree Report", "2019 Top 100 Future Healthcare Companies Analysis Report", "2019 Medical Artificial Intelligence Industry Development Report", "2019 Internet Hospital Industry Development Report", "Pharmaceutical Digital Innovation Report"More forum reports will be released on-site.

This industry conference is tailor-made for “you” if you are a government official or healthcare practitioner focused on the health and medical sector; a professional across the related industrial chain, including leaders of healthcare IT companies, medical device manufacturers, pharmaceutical firms, and insurance companies; industry investors; healthcare media professionals; or executives from publicly listed companies and startups that have deployed big data and AI-powered healthcare solutions.